Short communicationPublished 20 Jan 2021

GLIA-Deep: Glioblastoma Image Analysis using Deep Learning Convolutional Neural Networks to Accurately Classify Gene Methylation and Predict Drug Effectiveness

Authors: Viraj Mehta

Cancer Biology and Therapeutic Oncology

Volume 5 · Issue 1 · Pages 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Glioblastoma multiforme is a deadly brain cancer with a median patient survival time of 18-24 months, despite aggressive treatments. This limited success is due to a combination of aggressive tumor behavior, genetic heterogeneity of the disease within a single patient’s tumor, resistance to therapy, and lack of precision medicine treatments. A single specimen using a biopsy cannot be used for complete assessment of the tumor’s microenvironment, making personalized care limited and challenging. Temozolomide (TMZ) is a commercially approved alkylating agent used to treat glioblastoma, but around 50% of temozolomide-treated patients do not respond to it due to the over-expression of O6-methylguanine methyltransferase (MGMT). MGMT is a DNA repair enzyme that rescues tumor cells from alkylating agent-induced damage, leading to resistance to chemotherapy drugs. Epigenetic silencing of the MGMT gene by promoter methylation results in decreased MGMT protein expression, reduced DNA repair activity, increased sensitivity to TMZ, and longer survival time. Thus, it is paramount that clinicians determine the methylation status of patients to provide personalized chemotherapy drugs. However, current methods for determining this via invasive biopsies or manually curated features from brain MRI (Magnetic Resonance Imaging) scans are time- and cost- intensive and have a very low accuracy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

More from this journal

The newest in Cancer Biology and Therapeutic Oncology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Biology and Therapeutic Oncology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Viraj Mehta”